Researchers at Stanford have developed engineered IL-2 "surrogate" mutant agonists with varying patterns of STAT1/3/5, ERK, and PI3K signaling, as well as preferential induction of memory T cell differentiation and NK cell cytotoxicity relative to native IL-2.
Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.
Researchers at Stanford and their colleagues have developed easily expressed Wnt agonist and antagonists. Wnts are central mediators of development as they influence cell proliferation, differentiation and migration.
Researchers from Stanford developed recombinant polypeptide-cytokine conjugates and methods to induce antigen-specific regulatory T cells (Treg) for the treatment of inflammatory and autoimmune diseases.
Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity.
This L203 antibody may prove useful for research and diagnostic products in the detection of HLA, or on blood cells and/or in blood products such as plasma and serum; and the detection of soluable or cell associated HLA, or associated blood pathogens.
Rat monoclonal antibody isotype IgG2a (clone #153) recognizes the HA peptide sequence [YPYDVPDYA] derived from the influenza hemagglutinin protein. The HA peptide can be added to unrelated proteins through recombinant techniques.
Circulating levels of Neuromedin U (NMU) peptide are correlated with insulin resistance and obesity and dynamically regulated to suppress insulin secretion.
A team of Stanford researchers has developed humanized and chimeric mouse anti-human CD99 monoclonal antibodies with demonstrated activity against AML (acute myeloid leukemia) cells in vitro and in vivo.
Stanford researchers have developed a novel monoclonal antibody to the rat NKG2D protein, a major triggering receptor of Natural Killer (NK) cells and T cells. This receptor is known to play a role in viral infections, tumor defenses, and transplantation.
Researchers at Stanford have created a monoclonal antibody to CD6. CD6 is a surface molecule expressed on T cells and some B cells. It may also play a role in diseases such as multiple sclerosis and rheumatoid arthritis.